PureTech Reports LYT-200 Phase 1b Results, Plans Phase 2
PureTech reported a 45.5% overall response rate among 11 evaluable HR-MDS patients treated with LYT-200 plus HMA, with favorable safety. Gallop plans a 125-patient randomized Phase 2, subject to external capital.